Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Novel agents for treating neurological disorders disclosed in recent patent literature

May 23, 2006

Recent patents cover novel analgesic agents

May 23, 2006

Preclinical studies detail activity of asenapine

May 23, 2006

Phase II Oxycyte study in traumatic brain injury reaches treatment half-way post

May 23, 2006

Recent patents disclose new therapeutics for psychological disorders

May 22, 2006

Promising phase II results reported for leuprolide in Alzheimer's disease treatment

May 22, 2006

Collaboration to develop treatment for spinal muscular atrophy

May 22, 2006

Amarin acquires rights to novel formulation of apomorphine

May 22, 2006

Novel triple reuptake inhibitor shows antidepressant activity in animal models

May 19, 2006

FDA approves Azilect for Parkinson's disease

May 19, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...